SUPLLEMENTAL FIGURE LEGENDS
Supplemental Figure 1. Knockdown efficiency and necrosome formation in
murine fibroblasts
(A,B) L929 cells were transfected with siRNA for 2 days as indicated and analyzed
by IB. (C) WT MEFs were transfected and analyzed as above. (D,E) TRAF2 KO MEFs
were transfected and analyzed as above. (F) WT and TRAF2 KO MEFs were analyzed
by RIPK1 IP, followed by IB to verify the ability of the antibody to IP the target. (G)
WT and TRAF2 KO MEFs were treated as indicated and analyzed by RIPK3 IP
followed by RIPK1 IB. (H) WT MEFs were analyzed for necrosome formation at
extended time points by RIPK3 IP and IB as indicated. (I) L929 cells were
transfected with siRNA as indicated for 2 days, treated with CZ for 1 hr followed by
T for 1 hr, and analyzed by IP and IB as indicated.
Supplemental Figure 2. Validation of MLKL and TRAF2 antibodies and analysis
of TRAF2-MLKL interaction
(A) Expression of WT TRAF2 and mutant forms in TRAF2 KO MEFs. (B,C) WT and
TRAF2 KO MEFs were harvested and analyzed by MLKL IP followed by MLKL IB (A),
or TRAF2 IP followed by TRAF2 IB (B). (D) WT MEFs were treated as indicated and
analyzed for TRAF2-MLKL interaction by TRAF2 IP followed by MLKL or TRAF2 IB.
(E) L929 cells were treated as indicated for 90 min and analyzed by
immunofluorescence (IF) with specific antibodies to MLKL (left panels) or TRAF2
(center panels) or both (right panels).
1
Supplemental Figure 3. Analysis of ubiquitination and interaction of RIPK1
and TRAF2 during TNF-induced necroptosis
(A) WT and TRAF2 KO cells were treated for with CZ for 1 hr followed by T for the
indicated times. Cells were and analyzed by TRAF2 IP followed by IB with antiubiquitin (Ub) antibody. (B) L929 cells were pretreated for 1 hr with zVAD (Z) (20
M), cycloheximide (C) (1 g/ml) for 1 hr followed by TNF (T) (100 ng/ml) for the
indicated times. Cells were analyzed by IP of RIPK1 followed by IB as indicated. (C)
L929 cells were treated as in B for the indicated times. Cells were analyzed by RIPK1
IP followed by RIPK1 or ubiquitin IB. (D) Recombinant TRAF2 was incubated with
cIAP1 and ubiquitin, followed by incubation with recombinant MLKL in the absence
or presence of CYLD. TRAF2 binding to MLKL and TRAF2 ubiquitination were
analyzed by TRAF2 IP followed by IB as indicated.
Supplemental Figure 4. Verification of TRAF2 and RIPK3 KO and consequent
impact on body weight, necrosome formation, and caspase activation
(A) Cre-/- and cre+/+ mice were injected with tamoxifen (40 mg/kg) daily for 5 days
and monitored for morbidity. (B) Intestines from WT and TRAF2 KO mice were
collected 3 days after the last tamoxifen injection (day 8) and extracts were
analyzed by IB. (C) WT and TRAF2 KO mice were weighed on day 8. (D) Intestinal
extracts were collected and analyzed for necrosome formation by RIPK3 IP and IB
as indicated. (E) Intestinal extracts were collected from RIPK3 KO and TRAF2/RIPK3
DKO mice as in B and analyzed by IB. (F) Total RNA was isolated from intestines of
2
WT, TRAF2 KO, RIPK3 KO and TRAF2/RIPK3 DKO mice treated as in B and analyzed
for caspase-8 mRNA by quantitative RT-PCR. (G) WT, TRAF2 KO, RIPK3 KO and
TRAF2/RIPK3 DKO mice were injected with tamoxifen as in A. Livers were harvested
on day 8 and analyzed by IB. (H) Livers from WT, TRAF2 KO or TRAF2/RIPK3 DKO
mice were collected on day 8 and extracts were analyzed for caspase-8 (top panel)
and caspase-3/7 activity (bottom panel). Data in panels C, F and H depict
mean±SEM (n=4). P values are by Student’s t test.
Supplemental Figure 5. Inhibition of hepatic necrosome formation by
combined blockade of death ligands in TRAF2 KO mice
(A) WT and TRAF2 KO mice were injected with tamoxifen (20 mg/kg) daily for 5
days and concurrently with CD4-Fc (30 g/mouse), or a combination of TNFR1-Fc,
DR5-Fc and Fas-Fc (10 g/mouse each). Representative images depicting the
abdominal cavity of mice treated as in A. (B) Mice were treated as in A and weighed
on day 8. (C) Livers were collected on day 8 and extracts were analyzed by IP and IB
for necrosome formation. Data in panel B depict mean±SEM (n=4). P values are by
Student’s t test.
3
References
1.
Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, et al. RIP3, an energy
metabolism regulator that switches TNF-induced cell death from apoptosis to
necrosis. Science. 2009;325(5938):332-6.
2.
He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting
protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell.
2009;137(6):1100-11.
3.
Ashkenazi A, Salvesen G. Regulated Cell Death: Signaling and Mechanisms.
Annu Rev Cell Dev Biol. 2014.
4.
Salvesen GS, Ashkenazi A. Snapshot: caspases. Cell. 2011;147(2):476- e1.
5.
Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al.
Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed
necrosis and virus-induced inflammation. Cell. 2009;137(6):1112-23.
6.
Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase
domain-like is a key receptor interacting protein 3 downstream component of TNFinduced necrosis. Proc Natl Acad Sci U S A. 2012;109(14):5322-7.
7.
Robinson N, McComb S, Mulligan R, Dudani R, Krishnan L, Sad S. Type I
interferon induces necroptosis in macrophages during infection with Salmonella
enterica serovar Typhimurium. Nat Immunol. 2012;13(10):954-62.
8.
Mocarski ES, Upton JW, Kaiser WJ. Viral infection and the evolution of
caspase 8-regulated apoptotic and necrotic death pathways. Nat Rev Immunol.
2012;12(2):79-88.
9.
Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, et al. The
RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for
programmed necrosis. Cell. 2012;150(2):339-50.
10.
Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, et
al. The pseudokinase MLKL mediates necroptosis via a molecular switch
mechanism. Immunity. 2013;39(3):443-53.
11.
Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase
domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell.
2012;148(1-2):213-27.
12.
Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, et al. Mixed lineage kinase
domain-like protein MLKL causes necrotic membrane disruption upon
phosphorylation by RIP3. Mol Cell. 2014;54(1):133-46.
13.
Galluzzi L, Kepp O, Kroemer G. MLKL regulates necrotic plasma membrane
permeabilization. Cell research. 2014;24(2):139-40.
14.
Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A,
Bruggeman I, et al. MLKL compromises plasma membrane integrity by binding to
phosphatidylinositol phosphates. Cell Rep. 2014;7(4):971-81.
15.
Chen X, Li W, Ren J, Huang D, He WT, Song Y, et al. Translocation of mixed
lineage kinase domain-like protein to plasma membrane leads to necrotic cell death.
Cell research. 2014;24(1):105-21.
16.
Zhou W, Yuan J. Necroptosis in health and diseases. Semin Cell Dev Biol.
2014.
4
17.
Linkermann A, Hackl MJ, Kunzendorf U, Walczak H, Krautwald S, Jevnikar
AM. Necroptosis in immunity and ischemia-reperfusion injury. Am J Transplant.
2013;13(11):2797-804.
18.
Linkermann A, Brasen JH, Himmerkus N, Liu S, Huber TB, Kunzendorf U, et al.
Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes
to renal ischemia/reperfusion injury. Kidney Int. 2012;81(8):751-61.
19.
Welz PS, Wullaert A, Vlantis K, Kondylis V, Fernandez-Majada V, Ermolaeva
M, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal
inflammation. Nature. 2011;477(7364):330-4.
20.
Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, et al.
Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent
necrosis. Nature. 2011;471(7338):363-7.
21.
Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP,
Hakem R, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice.
Nature. 2011;471(7338):368-72.
22.
Bonnet MC, Preukschat D, Welz PS, van Loo G, Ermolaeva MA, Bloch W, et al.
The adaptor protein FADD protects epidermal keratinocytes from necroptosis in
vivo and prevents skin inflammation. Immunity. 2011;35(4):572-82.
23.
Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K,
Deshayes K, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by
preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death
Differ. 2011;18(4):656-65.
24.
O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, et al.
Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol.
2011;13(12):1437-42.
25.
Wu J, Huang Z, Ren J, Zhang Z, He P, Li Y, et al. Mlkl knockout mice
demonstrate the indispensable role of Mlkl in necroptosis. Cell research.
2013;23(8):994-1006.
26.
Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al.
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that
promote RIP1 ubiquitination. Mol Cell. 2008;30(6):689-700.
27.
Rodrigue-Gervais IG, Labbe K, Dagenais M, Dupaul-Chicoine J, Champagne C,
Morizot A, et al. Cellular inhibitor of apoptosis protein cIAP2 protects against
pulmonary tissue necrosis during influenza virus infection to promote host survival.
Cell Host Microbe. 2014;15(1):23-35.
28.
Jacquel A, Auberger P. cIAPs and XIAP reduce RIPKs to silence. Blood.
2014;123(16):2445-6.
29.
Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the
TNFalpha-induced necrosome to facilitate kinase activation and programmed
necrosis. PLoS One. 2013;8(10):e76841.
30.
Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, et al.
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to
efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem.
2009;284(51):35906-15.
5
31.
Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal
transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor
receptor 1 signaling complex. Proc Natl Acad Sci U S A. 1996;93(24):13973-8.
32.
Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD
interactions define two distinct TNF receptor 1 signal transduction pathways. Cell.
1996;84(2):299-308.
33.
Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NFkappa B by TNF receptor 2 and CD40. Science. 1995;269(5229):1424-7.
34.
Gonzalvez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, et al. TRAF2 Sets a
threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer.
Mol Cell. 2012;48(6):888-99.
35.
Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, et al. Early
lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced
cell death in TRAF2-deficient mice. Immunity. 1997;7(5):715-25.
36.
Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is
essential for JNK but not NF-kappaB activation and regulates lymphocyte
proliferation and survival. Immunity. 1997;7(5):703-13.
37.
Piao JH, Hasegawa M, Heissig B, Hattori K, Takeda K, Iwakura Y, et al. Tumor
necrosis factor receptor-associated factor (TRAF) 2 controls homeostasis of the
colon to prevent spontaneous development of murine inflammatory bowel disease. J
Biol Chem. 2011;286(20):17879-88.
38.
Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M, et
al. TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis. Cell Death
Dis. 2014;5:e1444.
39.
Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular
mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol.
2010;11(10):700-14.
40.
Gentle IE, Wong WW, Evans JM, Bankovacki A, Cook WD, Khan NR, et al. In
TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1,
which limits induction of non-canonical NF-kappaB and activation of caspase-8. J
Biol Chem. 2011;286(15):13282-91.
41.
Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2. Distinct domains for
nuclear factor-kappaB activation and association with tumor necrosis factor
signaling proteins. J Biol Chem. 1996;271(33):19935-42.
42.
Sondarva G, Kundu CN, Mehrotra S, Mishra R, Rangasamy V, Sathyanarayana
P, et al. TRAF2-MLK3 interaction is essential for TNF-alpha-induced MLK3
activation. Cell research. 2010;20(1):89-98.
43.
Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G.
The tumour suppressor CYLD negatively regulates NF-kappaB signalling by
deubiquitination. Nature. 2003;424(6950):801-5.
44.
Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos
G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB
activation by TNFR family members. Nature. 2003;424(6950):793-6.
45.
Lietke CG, N.; Manns, M. and Trautwein C. Interferon-alpha enhances TRAILmediated apoptosis by up-regulating caspase-8 transcription in human hepatoma
cells. Journal of Hepatology. 2006;44:342-9.
6
46.
Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370(5):455-65.
47.
Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment
of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity.
1996;4(4):387-96.
48.
Wong WW, Gentle IE, Nachbur U, Anderton H, Vaux DL, Silke J. RIPK1 is not
essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ.
2010;17(3):482-7.
49.
Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D, et al.
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or
apoptosis. Science. 2014;343(6177):1357-60.
50.
Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, et al. RIPK1
regulates RIPK3-MLKL-driven systemic inflammation and emergency
hematopoiesis. Cell. 2014;157(5):1175-88.
51.
Takahashi N, Vereecke L, Bertrand MJ, Duprez L, Berger SB, Divert T, et al.
RIPK1 ensures intestinal homeostasis by protecting the epithelium against
apoptosis. Nature. 2014;513(7516):95-9.
52.
Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L, et al.
RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis.
Nature. 2014;513(7516):90-4.
53.
Yang CH, Murti A, Pfeffer SR, Fan M, Du Z, Pfeffer LM. The role of TRAF2
binding to the type I interferon receptor in alternative NF kappaB activation and
antiviral response. J Biol Chem. 2008;283(21):14309-16.
54.
Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, et al.
Protection against endotoxic shock by a tumor necrosis factor receptor
immunoadhesin. Proc Natl Acad Sci U S A. 1991;88(23):10535-9.
55.
Ashkenazi A, Chamow SM. Immunoadhesins as research tools and
therapeutic agents. Curr Opin Immunol. 1997;9(2):195-200.
56.
Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappa
Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and
Toll-like receptors 2 and 4. Mol Cell Biol. 2004;24(4):1464-9.
7